Bacil Pharma has received approval from the Registrar of Companies, Central Registration Centre (CRC), for the name “Bacil Research & Development Private Limited” for its proposed wholly-owned subsidiary. The approval, dated July 6, 2026, grants the company the right to use the name for a period of 20 days, valid until July 26, 2026. This move marks a step forward in the company's expansion strategy through the establishment of a new subsidiary focused on research and development.

The name reservation was applied for on July 3, 2026, and subsequently approved by Charan Singh, Assistant Registrar of Companies. The approval letter explicitly states that the company cannot commence business or enter into any agreements until a Certificate of Registration is issued by the Registrar of Companies under the provisions of the Companies Act, 2013. The incorporation process is currently under progress, and the company intends to make necessary disclosures upon completion.

Regulatory Compliance and Validity

The approval is subject to specific conditions and timelines. The name availability is valid for 20 days from the date of approval, and the name may be withdrawn if found to be non-compliant with regulations at a later stage. The company must complete the incorporation process within this validity period to secure the name permanently.

The disclosure was made to the BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Chaitali Kalpataru Shah, Director of Bacil Pharma, on July 7, 2026.

Key Details of the Name Approval

The company has assured that it will take all necessary steps to complete the incorporation and will inform the exchanges upon receipt of the Certificate of Incorporation.

Bacil Pharma Limited has proposed the appointment of Mr. Vivek Mukesh Yadav and Mr. Omprakash Pyarelal Sonar as Non-executive Independent Directors to strengthen its board's expertise in finance and market growth. The appointments, subject to shareholder approval at the next General Meeting, aim to enhance the company's financial strategy and operational presence. The intimation was submitted to BSE Limited on June 30, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Mr. Vivek Mukesh Yadav (DIN: 11033957) brings significant experience in finance, accounts, and corporate management. His background includes reporting, financial planning, and compliance with regulatory frameworks, which the company expects will contribute to its financial and operational strategy. Mr. Yadav is not related to any of the existing directors of the company.

Mr. Omprakash Pyarelal Sonar (DIN: 11031877) is a professional in the trading industry with over seven years of experience. His expertise lies in product sales, brand establishment, and online sales strategies, which have been instrumental in driving market growth. Similar to Mr. Yadav, he is not related to any of the company's current directors.

The board will consider these resolutions in its upcoming meeting. The appointments are designated as Additional Non-executive Independent Director roles until ratified by the shareholders. The filing was signed by Ms. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited.

Proposed Appointments